ストックスクリーナーアプリを入手
3.29
4.78%
-0.165
前日終値:
$3.455
開ける：
$3.45
24時間の取引高:
18,673
Relative Volume:
0.33
時価総額：
$22.52M
収益：
$5.75M
当期純損益:
$-38.96M
株価収益率:
-0.2638
EPS:
-12.47
ネットキャッシュフロー:
$-32.63M
1週間 パフォーマンス:
-5.73%
1か月 パフォーマンス:
-52.46%
6か月 パフォーマンス:
-37.21%
1年 パフォーマンス:
-50.08%
1日の値動き範囲:
$3.2111
$3.45
1週間の範囲:
$3.2111
$3.75
52週間の値動き範囲:
$3.2111
$11.20
Kala Bio Inc Stock (KALA) Company Profile
KALA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
3.29 | 22.52M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-03-30 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-08-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-09-14 | ダウングレード | Jefferies | Buy → Hold |
| 2020-07-23 | 開始されました | Northland Capital | Outperform |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2020-05-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-09 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | 開始されました | Jefferies | Buy |
すべてを表示
Kala Bio Inc (KALA) 最新ニュース
Oppenheimer maintains Kala Bio stock Outperform with $15 target By Investing.com - Investing.com Canada
Kala Bio announces executive retention bonuses - Investing.com Australia
KALA stock touches 52-week low at $3.4 amid market challenges By Investing.com - Investing.com South Africa
Kala Bio announces executive retention bonuses By Investing.com - Investing.com South Africa
Kala Pharmaceuticals Announces Executive Retention Agreements - TipRanks
KALA stock touches 52-week low at $3.4 amid market challenges - Investing.com
Dynatrace, Inc. (NYSE:DT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Darling Ingredients Inc. (NYSE:DAR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Truist Financial Lowers Bank of New York Mellon (NYSE:BK) Price Target to $90.00 - Defense World
HC Wainwright Reaffirms “Buy” Rating for KALA BIO (NASDAQ:KALA) - Defense World
Kala Pharmaceuticals stock hits 52-week low at $4.05 - Investing.com India
Kala Pharmaceuticals stock hits 52-week low at $4.05 By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Kala Bio, target at $15 By Investing.com - Investing.com Canada
Kala Bio Inc Reports Q4 2024 Earnings: EPS Misses Estimate at -2 - GuruFocus
Simply Good Foods (SMPL) Expected to Announce Earnings on Wednesday - The AM Reporter
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock - Investing.com Australia
Oppenheimer maintains Outperform on Kala Pharmaceuticals stock By Investing.com - Investing.com UK
KALA BIO: Q4 Earnings Snapshot - Huron Daily Tribune
KALA BIO Advances Eye Disease Therapies with New Funding - TipRanks
KALA BIO Inc. (KALA) reports earnings - Quartz
KALA BIO, Inc. SEC 10-K Report - TradingView
KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - TradingView
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
KALA BIO (KALA) Projected to Post Quarterly Earnings on Friday - Defense World
KALA BIO Inc expected to post a loss of $2.28 a shareEarnings Preview - TradingView
Comprehensive Insights of the Global Acute Ocular Pain Market: Key Drivers, Trends, Growth Opportunities, a... - WhaTech
KALA BIO (KALA) Expected to Announce Quarterly Earnings on Thursday - Defense World
Kala Bio appoints new interim CEO amid leadership shuffle - MSN
KALA BIO to Present at TD Cowen 45th Annual Health Care Conference - TradingView
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - The Manila Times
What Will KALA BIO Reveal at the TD Cowen Healthcare Conference Next Week? - StockTitan
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN
Precision Bio stock gains on Hep B drug data (DTIL:NASDAQ) - Seeking Alpha
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth - The Manila Times
Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth - GlobeNewswire
Major Leadership Shake-up: Pharma Veteran Takes Helm at Inhibikase with $110M War Chest - StockTitan
KALA BIO's (KALA) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Kala Bio Inc (NASDAQ: KALA) Has Been Trading Down. What Are The Prospects For The Future? - Stocks Register
KALA BIO says CEO Mark Iwicki resigns - MSN
Kala Bio Inc (KALA) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):